系统性红斑狼和系统性硬化症中的间歇性肺病:我们如何应对挑战?
Patricia Richter1,2, Anca Cardoneanu1,2, Nicoleta Dima3,4
1Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
International journal of molecular sciences
|June 10, 2023
概括
系统性红斑狼 (SLE) 和系统性硬化症 (SSc) 中的间歇性肺病 (ILD) 需要更好地识别和管理. 宁达尼布在治疗SSc-ILD方面表现有前途,但SLE-ILD需要进一步研究.
科学领域:
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
- 内部医学 内部医学
背景情况:
- 间歇性肺部疾病 (ILD) 是连接组织疾病 (CTD) 的重要并发症,影响患者的发病率和死亡率.
- 系统性红斑狼 (SLE) 中ILD的患病率和诊断标准仍在争论中,需要排除重叠综合征.
- 在系统性硬化症 (SSc) 中,ILD是导致死亡的主要原因,发病率因亚型和诊断方法而异.
研究的目的:
- 审查有关SLE相关ILD和SSc相关ILD的诊断和管理的当前发现.
- 提高人们对这些衰弱状况的识别和治疗的认识.
- 突出最近的治疗进展,特别是对于SSc-ILD.
主要方法:
- 最近研究和临床试验的文献综述.
- 对SLE和SSc中的ILD诊断挑战和治疗策略的分析.
- 综合关于治疗疗效和患者结果的证据.
主要成果:
- 与SLE相关的ILD诊断需要仔细排除其他疾病,并越来越多地将其确定为临床目标.
- 由于其高患病率和死亡率,SSc相关的ILD需要在诊断时和整个疾病过程中进行查.
- 与安慰剂相比,丁丁达尼布是一种铁氨酸激酶抑制剂,在SSc中显示ILD进展率降低.
结论:
- 改进的诊断策略和提高认识对于在SLE和SSc.中管理ILD至关重要.
- 丁丁达尼布代表了一种有前途的治疗选择,可以减缓SSc相关的ILD进展.
- 对于与SLE相关的ILD治疗,需要进行进一步的安慰剂对照研究.
相关概念视频
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
01:24Cystic Fibrosis: Management
199
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
199
01:30Chronic Obstructive Pulmonary Disease-V: Nursing Management
4.0K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Assessment
4.0K
01:17Drugs Used in Lower Respiratory Disorders: Overview
506
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
506
01:28Pleural Effusion II: Symptoms and Management
221
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
221